Clinical pharmacology of antifungal agents in pediatric patients

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 15, 2007, Pages 2465-2489

  Chiou, Christine C ^a   Walsh, Thomas J ^a   Groll, Andreas H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Amphotericin; Anidulafungin; Antifungal agent; Caspofungin; Children; Fluconazaole; Flucytosine; Itraconazole; Micafungin; Mycoses; Pharmacology; Posaconazole; Voriconazole

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; DEXAMETHASONE; ECHINOCANDIN; EFAVIRENZ; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; HYDROCORTISONE; ITRACONAZOLE; MICAFUNGIN; NELFINAVIR; NEVIRAPINE; PARACETAMOL; PETHIDINE; PHENYTOIN; POSACONAZOLE; RIFAMPICIN; TACROLIMUS; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ABNORMAL VISION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; ASPERGILLUS TERREUS; BILIRUBIN BLOOD LEVEL; BLASTOMYCOSIS; BLURRED VISION; BONE MARROW TOXICITY; BRONCHOSPASM; CANCER PATIENT; CANDIDA; CANDIDA GLABRATA; CANDIDEMIA; CANDIDIASIS; CHILD CARE; CHILL; CHROMOMYCOSIS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; COMBINATION CHEMOTHERAPY; CONFUSION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; DERMATOMYCOSIS; DIARRHEA; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FEVER; FLANK PAIN; FLUSHING; FUSARIUM; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARREST; HEART ARRHYTHMIA; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; IMMUNOCOMPROMISED PATIENT; KIDNEY CONCENTRATING CAPACITY; KIDNEY TUBULE ACIDOSIS; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LOADING DRUG DOSE; MAGNESIUM DEPLETION; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCORMYCOSIS; MYALGIA; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NEWBORN INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; PHOTOSENSITIVITY; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PLASMA HALF LIFE; POTASSIUM DEPLETION; RECOMMENDED DRUG DOSE; RESPIRATORY DISTRESS; REVIEW; RIGOR; SALVAGE THERAPY; SCEDOSPORIUM; SIDE EFFECT; SINGLE DRUG DOSE; SKIN EXFOLIATION; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; SURVIVAL RATE; THORAX PAIN; TRICHOSPORON ASAHII; UNSPECIFIED SIDE EFFECT; UREMIA; VESTIBULAR DISORDER; VISUAL DISORDER; VOMITING;

AGE FACTORS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHILD; HUMANS; MYCOSES; PHARMACOLOGY, CLINICAL;

EID: 35748933879     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.15.2465     Document Type: Review

References (174)

1. BRAJTBURG J, POWDERLY WG, KOBAYASHI GS, MEDOFF G: Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother. (1990) 34(2):183-188.
2. GROLL AH, WALSH TJ: Uncommon opportunistic fungi: new nosocomial threats. Clin. Microbiol. Infect. (2001) 7(Suppl. 2):8-24.
3. CHRISTIANSEN KJ, BERNARD EM, GOLD JW, ARMSTRONG D: Distribution and activity of amphotericin B in humans. J. Infect. Dis. (1985) 152(5):1037-1043.
4. BEKERSKY I, FIELDING RM, DRESSLER DE et al.: Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. (2002) 46(3):834-840.
5. BEKERSKY I, FIELDING RM, DRESSLER DE et al.: Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. (2002) 46(3):828-833.
6. STARKE JR, MASON EO Jr, KRAMER WG, KAPLAN SL: Pharmacokinetics of amphotericin B in infants and children. J. Infect, Dis. (1987) 155(4):766-774.
7. KOREN G, LAU A, KLEIN J et al.: Pharmacokinetics and adverse effects of amphotericin B in infants and children. J. Pediatr. (1988) 113(3):559-563.
8. BENSON JM, NAHATA MC: Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. (1989) 33(11):1989-1993.
9. BALEY JE, MEYERS C, KLIEGMAN RM, JACOBS MR, BLUMER JL: Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. (1990) 116(5):791-797.
10. NATH CE, SHAW PJ, GUNNING R, MCLACHLAN AJ, EARL JW: Amphotericin B in children with malignant disease: a comparison of the toxicities an pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. Antimicrob. Agents Chemother. (1999) 43(6):1417-1423.
11. ARNING M, KLICHE KO, HEER-SONDERHOFF AH, WEHMEIER A: Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses (1995) 38(11-12):459-465.
12. WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. Nationl institute of allergy and infectious diseases mycoses study group. N. Engl. J. Med. (1999) 340(10):764-771.
13. NATH CE, MCLACHLAN AJ, SHAW PJ, GUNNING R, EARL JW: Population pharmacokinetics of amphotericin B in children with malignant diseases. Br. J. Clin. Pharmacol. (2001) 52(6):671-680.
14. KINGO AR, SMYTH JA, WAISMAN D: Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr. Infict. Dis. J. (1997) 16(10):1002-1003.
15. WALSH TJ, GONZALEZ C, LYMAN CA, CHANOCK SJ, PIZZO PA: Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv. Pediatr. Infect. Dis. (1996) 11:187-290.
16. GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. (1998) 44:343-500.
17. BUTLER WT, BENNETT JE, ALLING DW et al.: Nephrotoxicity of amphotericin B; early and late effects in 81 patients. Ann. Inter. Med. (1964) 61:175-187.
18. GOOGE JH, WALTERSPIEL JN: Arrhythmia caused by amphotericin B in a neonate. Pediatr. Infect. Dis. J. (1988) 7(1):73.
19. SAWAYA BP, BRIGGS JP, SCHNERMANN J: Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. (1995) 6(2):154-164.
20. WHITE MH, BOWDEN RA, SANDLER ES et al.: Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1998) 27(2):296-302.
21. PRENTICE HG, HANN IM, HERBRECHT R et al.: A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. (1997) 98(3):711-718.
22. BUTLER KM, RENCH MA, BAKER CJ: Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr. Infect. Dis. J. (1990) 9(1):51-56.
23. LEIBOVITZ E, IUSTER-REICHER A, AMITAI M, MOGILNER B: Systemic candidal infections associated with use of peripheral venous catheters in neonates: a 9-year experience. Clin. Infect. Dis. (1992) 14(2):485-491.
24. GLICK C, GRAVES GR, FELDMAN S: Neonatal fungemia. and amphotericin B. South Med. J. (1993) 86(12):1368-1371.
25. BALEY JE, KLIEGMAN RM, FANAROFF AA: Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics (1984) 73(2):153-157.
26. WALSH TJ, HIEMENZ JW, ANAISSIE E: Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect. Dis. Clin. North Am. (1996) 10(2):365-400.
27. HEIDEMANN HT GERKENS JF, SPICKARD W&, JACKSON EK, BRANCH RA: Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. (1983) 75(3):476-481.
28. ARNING M, SCHARF RE: Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin. Wochenschr. (1989) 67(20):1020-1028.
29. HOLLER B, OMAR SA, FARID MD, PATTERSON MJ: Effects of fluid and electrolyte management on amphotericin B-induced nephroroxicity among extremely low birth weight infants. Pediatrics (2004) 113(6):E608-E616.
30. GROLL AH, WALSH TJ: Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly. (2002) 132(23-24):303-311.
31. GROLL AH, MULLER FM, PISCITELLI SC, WALSH TJ: Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin. Padiatr. (1998) 210(4):264-273.
32. HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22(Suppl. 2):S133-S144.
33. GROLL AH, GEA-BANACLOCHE JC, GLASMACHER A et al.: Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. North Am. (2003) 17(1):159-191.
34. BOUCHER HW, GROLL AH, CHIOU CC, WALSH TJ: Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs (2004) 64(18):1997-2020.
35. ANAISSIE E WHITE M, UZUN O et al.: Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC (1995):330 (Abstract LM 21).
36. AMANTEA MA, BOWDEN RA, FORREST A et al.: Population pharmacokinctics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob. Agents Chemother. (1995) 39(9):2042-2047.
37. SANDLER ES, MUSTAFA MM, TKACZEWSKI I et al.: Use of amphotericin B colloidal dispersion in children. J. Pediatr. Hematol, Oncol. (2000) 22(3):242-246.
38. WALSH TJ, WHITCOMB P, PISCITELLI S et al.: Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. (1997) 41(9):1944-1948.
39. WALSH TJ, SEIBEL NL, ARNDT C et al.: Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect. Dis, J. (1999) 18(8):702-708.
40. WILEY JM, SEIBEL NL, WALSH TJ: Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect. Dis. J. (2005) 24(2):167-174.
41. WURTHWEIN G, GROLL AH, HEMPEL G et al.: Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob. Agents Chemother. (2005) 49(12):5092-5098.
42. SEIBEL N, WALSH TJ: Safety, tolerance and pharmacokinetics of liposomal amphotericin B in children and adolescents. Abstracts of Focus on Fungal Infections. Imedex, Alfaretta, GA (1999):17.
43. HONG Y, SHAW PJ, NATH CE et al.: Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases. Antimicrob. Agents Chemother. (2006) 50(3):935-942.
44. MEUNIER F, PRENTICE HG, RINGDEN O: Liposomal amphotericin B (AmBisome): safety data from a Phase II/III clinical trial. J. Antimicro. Chemother. (1991) 28(Suppl. B):83-91.
45. PASIC S, FLANNAGAN L, CANT AJ: Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency. Bone Marrow Transplant. (1997) 19(12):1229-1232.
46. R with special emphasis on experience in children. Bone Marrow Transplant. (1993) 12(Suppl. 4):149-150.
47. DORNBUSCH HJ, URBAN CE, PINTER H et al.: Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: report of five cases. Pediatr. Hematol. Oncol. (1995) 12(6):577-586.
48. EMMINGER W, GRANINGER W, EMMINGER-SCHMIDMEIER W et al.: Tolerance of high doses of amphotericin B by infusion of a liposomal formulation in children with cancer. Ann. Hematol. (1994) 68(1):27-31.
49. KOLVE H, RITTER J, JUERGENS H, GROLL AH: Safety, tolerance and outcome of treatment with liposomal amphotericin B in pediatric cancer/HSCT patients. Bone Marrow Transplant. (2005) 35(Suppl. 2):S264-S265.
50. JUSTER-REICHER A, FLIDEL-RIMON O, AMITAY M et al.: High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur. J. Clin. Microbiol, Infect. Dis. (2003) 22(10):603-607.
51. JOHNSON MD, DREW RH, PERFECT JR. Chest discomfort associated with liposomal amphotericin B: report of three cases and review of the literature. Pharmacotherapy (1998) 18(5):1053-1061.
52. RODEN MM, NELSON LD, KNUDSEN TA et al.: Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics. Clin. Infect. Dis. (2003) 36(10):1213-1220.
53. BOWDEN R, CHANDRASEKAR P, WHITE MH et al.: A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin. Infect. Dis. (2002) 35(4):359-366.
54. CORNELY OJ, BRESNIK M, HERBRECHT R: Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin. Infect. Dis. (2007) 44:1289-1297.
55. KUSE ER, CHETCHOTISAD H, CUNHA C et al.: Micafungin invasive candidiasis working group. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a Phase III randomised double-blind trial. Lancet (2007) 369:1519-1527.
56. GROLL AH, RITTER J: Diagnosis and management of fungal infections and pneumocystis pneumonitis in pediatric cancer patients. Klin. Paediatr (2005) 217(Suppl. 1):S37-S66.
57. GROLL AH, WALSH TJ, YU VL, MERIGAN TC, BARRIERE SL (Eds): Antifungal triazoles. Antimicrobial Chemotherapy Vaccines. Williams and Wilkins, Baltimore (1998).
58. GOA KL, BARRADELL LB: Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs (1995) 50(4):658-690.
59. LEE JW, SEIBEL NL, AMANTEA M et al.: Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. (1992) 120(6):987-993.
60. BRAMMER KW, COATES PE: Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbio Infect. Dis. (1994) 13(4):325-329.
61. SAXEN H, HOPPU K, POHJAVUORI M: Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharm. Ther. (1993) 54(3):269-277.
62. KRZESKA I, YEATES RA, PFAFF G: Single dose intravenous pharmacokinetic of fluconazole in infants. Drugs Exp. Clin. Res. (1993) 19(6):267-271.
63. SEAY RE, LARSON TA, TOSCANO JP et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotheropy (1995) 15(1):52-58.
64. NAHATA MC, TALLIAN KB, FORCE RW. Pharmacokinetics of fluconazole in young infants. Eur. J. Drug Metabol. Pharmacokin. (1999) 24(2):155-157.
65. LOUIE A, DRUSANO GL, BANERJEE P et al.: Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob. Agents Chemother. (1998) 42(5):1105-1109.
66. ANDES D, VAN OGTROP M: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob. Agents Chemother. (1999) 43(9):2116-2120.
67. ANAISSIE EJ, KONTOYIANNIS DP, HULS C et al.: Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. Antimicrob. Agents Chemother. (1995) 172(2):599-602.
68. NOVELLI V, HOLZEL H: Safety and tolerability of fluconazole in children. Antimicrob. Agents Chemother. (1999) 43(8):1955-1960.
69. COMO JA, DISMUKES WE: Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. (1994) 330(4):263-272
70. PISCITELLI SC, FLEXNER C, MINOR JR, POLIS MA, MASUR H: Drug interactions in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1996) 23(4):685-693.
71. REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia study group and the National Institute. N. Engl J. Med. (1994) 331(20):1325-1330.
72. PHILLIPS R SHAFRAN S, GARBER G et at.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian candidemia study group. Eur. J. Clin. Microbiol. Infect. Dis. (1997) 16(5):337-345.
73. ANAISSIE EJ, DAROUICHE RO, ABI-SAID D et al.: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. (1996) 23(5):964-972.
74. ANAISSIE EJ, VARTIVARIAN SE, ABI-SAID D et al.: Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am. J. Med. (1996) 101(2):170-176.
75. FLYNN PM, CUNNINGHAM CK, KERKERING T et al.: Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The multicenter fluconazole study group. J. Pediatr. (1995) 127(2):322-328.
76. HERNANDEZ-SAMPELAYO T: Fluconazole versus ketoconazolc in the treatment of oropharyngeal candidiasis in HIV-infected children. Multicentre study group. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(4):340-344.
77. MARCHISIO P PRINCIPI N: Treatment of oropharyngeal candidiasis in HIV-infected children with oral fluconazole. Multicentre study group [corrected]. Eur. J. Clin. Microbiol. Infict. Dis. (1994) 13(4):338-340.
78. GROLL A, NOVAK-GOETTL U, WILDFEUER A, WEISE M, SCHWABE D, GEREIN V, KORNHUBER. B: Fluconazole treatment of oropharyngeal candidosis in pediatric cancer patients with severe mucositis following antineoplastic chemotherapy. Mycoses (1992) 35:35-40.
79. PAPPAS PG, REX JH, SOBEL JD et al. Guidelines for treatment of candidiasis. Clin. Infect. Dis. (2004) 38(2):161-189.
80. FASANO C, O'KEEFFE J, GIBBS D: Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(4):351-354.
81. BILGEN H, OZEK E, KORTEN V, ENER B, MOLBAY D: Treatment of systemic neonatal candidiasis with fluconazole. Infection (1995) 23(6):394.
82. DRIESSEN M, ELLIS JB, MUWAZI F, DE VILLIERS FP: The treatment of systemic candidiasis in neonates with oral fluconazole. Ann. Trop. Paediatr. (1997) 17(3):263-271.
83. DRIESSEN M, ELLIS JB, COOPER PA et al.: Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J. (1996) 15(12):1107-1112.
84. WAINER S, COOPER PA, GOUWS H, AKIERMAN A: Prospective study of fluconazole therapy in systemic neonatal fungal infection. Pediatr. Infect. Dis. J. (1997) 16(8):763-767.
85. HUTTOVA M, HARTMANOVA I, KRALINSKY K et al.: Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. (1998) 17(11):1012-1015.
86. NAISSIE E, BODEY GP, KANTARJIAN H et al.: Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am. J. Med. (1991) 91(2):142-150.
87. KAUFFMAN CA, BRADLEY SF, ROSS SC, WEBER DR. Hepatosplenic candidiasis: successful treatment with fluconazole. Am. J. Med. (1991) 91(2):137-141.
88. VAN DER HORST CM, SAAG MS, CLOUD GA et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of allergy and infectious diseases mycoses study group and AIDS clinical trials group. N. Engl. J. Med. (1997) 337(1):15-21.
89. SAAG MS, CLOUD GA, GRAYBILL JR et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National institute of allergy and infectious diseases mycoses study group. Clin. Infect. Dis. (1999) 28(2):291-296.
90. GALGIANI JN, CATANZARO A, CLOUD GA et al.: Fluconazole therapy for coccidioidal meningitis. The NIAID-mycoses study group. Ann. Inter. Med. (1993) 119(1):28-35.
91. CATANZARO A, GALGIANI JN, LEVINE BE et al.: Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID mycoses study group. Am. J. Med. (1995) 98(3):249-256.
92. DIAZ M, NEGRONI R, MONTERO-GEI F et al.: A Pan-American 5-year study of fluconazole therapy for deep mycoses in the immunocompetent host. Pan-American study group. Clin. Infect. Dis. (1992) 14(Suppl. 1):S68-S76.
93. PAPPAS PG, BRADSHER RW, CHAPMAN SW et al.: Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of allergy and infectious diseases mycoses study group. Clin. Infect. Dis. (1995) 20(2):267-271.
94. PAPPAS PG, BRADSHER RW, KAUFFMAN CA et al.: Treatment of blastomycosis with higher doses of fluconazole. The National Institute of allergy and infectious diseases mycoses study group. Clin. Infect. Dis. (1997) 25(2):200-205.
95. WHEAT J, MAWHINNEY S, HAFNER R et al.: Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of allergy and infectious diseases acquired immunodeficiency syndrome clinical trials group and mycoses study group. Am. J. Med. (1997) 103(3):223-232.
96. MCKINSEY DS, KAUFFMAN CA, PAPPAS PG et al.: Fluconazole therapy for histoplasmosis. The National of allergy and infectious diseases mycoses study group. Clin. Infect. Dis. (1996) 23(5):996-1001.
97. KAUFFMAN CA, PAPPAS PG, MCKINSEY DS et al.: Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin. Infect. Dis. (1996) 22(1):46-50.
98. POWDERLY WG, FINKELSTEIN D, FEINBERG J et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS clinical trials group. N. Engl. J. Med. (1995) 332(11):700-705.
99. NINANE J: A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre study group. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(4):330-337.
100. GROLL AH, JUST-NUEBLING G, KURZ M et al.: Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J. Antimicrob. Chemother. (1997) 40(6):855-862.
101. GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. (1992) 326(13):845-851.
102. SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171(6):1545-1552.
103. KAUFMAN D, BOYLE R, HAZEN KC et al.: Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. (2001) 345(23):1660-1666.
104. KAUFMAN D, BOYLE R, HAZEN KC et al.: Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of < 1000 grams birth weight. J. Pediatr. (2005) 147(2):172-179.
105. BERTINI G, PERUGI S, DANI C et al.: Fluconazole prophylaxis prevents invasive fungal infection in high-risk, very low birth weight infants. J. Pediatr. (2005) 147(2):162-165.
106. HEALY CM, BAKER CJ, ZACCARIA E, CAMPBELL JR: Impact of fluconazole prophylaxis on incidence and outcome of invasive candidiasis in a neonatal intensive care unit. J. Pediatr. (2005) 147(2):166-171.
107. MANZONI P, ARISIO R, MOSTERT M et al.: Prophylactic fluconazole is effective in preventing fungal colonization and fungal systemic infections in preterm neonates: a single-center, 6-year, retrospective cohort study. Pediatrics (2006) 117(1):E22-E32.
108. UKO S, SOGHIER LM, VEGA M et al.: Targeted short-term fluconazole prophylaxis among very low birth weight and extremely low birth weight infants. Pediatrics (2006) 117(4):1243-1252.
109. BARONE JA, MOSKOVITZ BL, GUARNIERI J et al.: Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers. Antimicrob. Agents Chemother. (1998) 42(7):1862-1865.
110. REYNES J, BAZIN C, AJANA F et al.: Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob. Agents Chemother. (1997) 41(11):2554-2558.
111. VANDEWOUDE K, VOGELAERS D, DECRUYENAERE J et al.: Concentration in plasma and safety of 7 days of intravenous itraconazole followed by 2 weeks of oral itraconazole solution in patients in intensive care units. Antimicrob. Agents Chemother. (1997) 41(12):2714-2718.
112. BOOGAERTS M, WINSTON DJ, BOW EJ et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Inter. Med. (2001) 135(6):412-422.
113. CAILLOT D, BASSARIS H, MCGEER A et al.: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin. Infect. Dis. (2001) 33(8):E83-E90.
114. DE REPENTIGNY L, RATELLE J, LECLERC JM et al.: Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob. Agents Chemother. (1998) 42(2):404-408.
115. GROLL AH, WOOD L, RODEN M et al.: Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. (2002) 46(8):2554-2563.
116. PRENTICE AG, WARNOCK DW, JOHNSON SA, TAYLOR PC, OLIVER DA: Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J. Antimicrob. Chemother. (1995) 36(4):657-663.
117. FOOT AB, VEYS PA, GIBSON BE: Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. (1999) 24(10):1089-1093.
118. ABDEL-RAHMAN SM, POWELL DA, NAHATA MC: Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis. J. Am. Acad. Dermatol. (1998) 38(3):443-446.
119. GRANT SM, CLISSOLD SP: Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs (1989) 37(3):310-344.
120. AANPREUNG P, VEERAKUL G: Itraconazole for treatment of oral candidosis in pediatric cancer patients. J. Med. Assoc. Thai. (1997) 80(6):358-362.
121. DENNING DW, TUCKER RM, HANSON LH, STEVENS DA: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. (1989) 86(6 Part 2):791-800.
122. STEVENS DA, LEE JY: Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID mycoses study group criteria. Arch. Intern. Med. (1997) 157(16):1857-1862.
123. SHARKEY PK, GRAYBILL JR, RINALDI MG et al.: Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. (1990) 23 (3 Part 2):577-586.
124. RESTREPO A, ROBLEDO J, GOMEZ I, TABARES, AM, GUTIERREZ R: Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch. Dermatol. (1986) 122(4):413-417.
125. NARANJO MS, TRUJILLO M, MUNERA MI et al.: Treatment of paracoccidioidomycosis with itraconazole. J. Med. Vet. Mycol. (1990) 28(1):67-76.
126. NEGRONI R, PALMIERI O, KOREN F, TIRABOSCHI IN, GALIMBERTI RL: Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans. Rev. Infect. Dis. (1987) 9(Suppl. 1):S47-S50.
127. DISMUKES WE, BRADSHER RW Jr, CLOUD GC et al.: Itraconazole therapy for blastomycosis and histoplasmosis. NIAID mycoses study group. Am. J. Med. (1992) 93(5):489-497.
128. TOBON AM, FRANCO L, ESPINAL D et al.: Disseminated histoplasmosis in children: the role of itraconazole therapy. Pediatr. Infect. Dis. J. (1996) 15(11):1002-1008.
129. WHEAT J, HAFNER R, KORZUN AH et al.: Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS clinical trial group. Am. J. Med. (1995) 98(4):336-342.
130. WHEAT J, HAFNER R, WULFSOHN M et al.: Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann. Inter. Med. (1993) 118(8):610-616.
131. TUCKER RM, DENNING DW, ARATHOON EG, RINALDI MG, STEVENS DA: Itraconazole therapy for nonmeningeal coccidioidomycosis: clinical and laboratory observations. J. Am. Acad. Dermatol. (1990) 23(3 Part 2):593-601.
132. TUCKER RM, DENNING DW, DUPONT B, STEVENS DA: Itraconazole therapy for chronic coccidioidal meningitis. Ann. Inter. Med. (1990) 112(2):108-112.
133. GRAYBILL JR, STEVENS DA, GALGIANI JN, DISMUKES WE, CLOUD GA: Itraconazole treatment of coccidioidomycosis. NAIAD mycoses study group. Am. J. Med. (1990) 89(3):282-290.
134. MENICHETTI F, DEL FAVERO A, MARTINO P et al.: Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA infection program. Gruppo Italiano Malattie Ematologiche dell'Adulto. Clin. Infect. Dis. (1999) 28(2):250-255.
135. WINSTON DJ, MAZIARZ RT, CHANDRASEKAR PH et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann. Inter. Med. (2003) 138(9):705-713.
136. MARR KA, CRIPPA F, LEISENRING W et al.: Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood (2004) 103(4):1527-1533.
137. GLASMACHER A, PRENTICE A, GORSCHLUTER M et al.: Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J. Clin. Oncol. (2003) 21(24):4615-4626.
138. FRANCIS P, WALSH TJ: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. (1992) 15(6):1003-1018.
139. POLAK A: Mode of action studies. In: Handbook of Experimental Pharmacology (Volume 96). Ryley JF (Ed.), Springer-Verlag Berlin (1990):153-182.
140. BENNETT JE, DISMUKES WE, DUMA RJ et al.: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. (1979) 301(3):126-131.
141. LARSEN RA, BOZZETTE SA, JONES BE et al.: Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. (1994) 19(4):741-745.
142. JOHNSON LB, KAUFFMAN CA: Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. (2003) 36(5):630-637.
143. PURKINS L, WOOD N, GHAHRAMANI P et al.: Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. (2002) 46(8):2546-2553.
144. ALLY R, SCHURMANN D, KREISEL W et al.: A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. (2001) 33(9):1447-1454.
145. HERBRECHT R, DENNING DW, PATTERSON TF et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. (2002) 347(6):408-415.
146. WALSH TJ, PAPPAS P, WINSTON DJ et al.: Variconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia. and persistent fever. N. Engl. J. Med. (2002) 346(4):225-234.
147. HEGENER P, TROKE PF, FATKENHEUER G, DIEHL V, RUHNKE M: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS (1998) 12(16):2227-2228.
148. DENNING DW, RIBAUD P, MILPIED N et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. (2002) 34(5):563-571.
149. PERFECT JR, MARR KA, WALSH TJ et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. (2003) 36(9):1122-1131.
150. KULLBERG BJ, SOBEL JD, RUHNKE M et al.: Variconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neuropenic patients: a randomised non-inferiority trial. Lancet (2005) 366(9495):1435-1442.
151. WALSH TJ, LUTSAR I, DRISCOLL T et al.: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Inject. Dis. J. (2002) 21(3):240-248.
152. SCHWARTZ S, RUHNKE M, RIBAUD P et al.: Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 106(8):2641-2645.
153. WALSH TJ, KARLSSON MO, DRISCOLL T et al.: Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob. Agents Chemother. (2004) 48(6):2166-2172.
154. WALSH TJ DT, ARIETTA AC, KLEIN N et al.: Pharmacokinetics, safety, and tolerability of voriconazole in hospitalized children. The 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, DC (2006): 406 (Abstr. M-887).
155. KOLVE H, EHLERT K, PAULUSSEN M et al.: Safety, tolerance and plasma concentrations of voriconazole in immunocompromised pediatric patients. Clin. Microbiol. Infect. (2004) 10(Suppl. 3):40-41.
156. GROLL AH, WALSH TJ: Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti. Infect. Ther. (2005) 3(4):467-487.
157. HERBRECHT R: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int. J. Clin. Pract. (2004) 58:612-624.
158. KRIETER P, FLANNERY B, MUSICK T et al.: Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. (2004) 48(9):3543-3551.
159. EZZET F, WEXLER D, COURTNEY R et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. (2005) 44(2):211-220.
160. RAAD II, GRAYBILL JR, BUSTAMANTE AB et al.: Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis. (2006) 42(12):1726-1734.
161. SKIEST DJ, VAZQUEZ JA, ANSTEAD GM et al.: Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. (2007) 44:607-614.
162. VAZQUEZ JA, SKIEST DJ, TISSOT-DUPONT H et al.: Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin. Trials (2007) 8:86-97.
163. RAAD I CS, BRADSHER R, MORRISON V et al.: Posaconazole salvage
164. VAZQUEZ JA, SKIEST DJ, NIETO L et al.: A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. (2006) 42(8):1179-1186.
165. VAN BURIK JA, HARE RS, SOLOMON HF, CORRADO ML, KONTOYIANNIS DP: Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. (2006) 42(7):E61-E65.
166. ULLMANN AJ LJ, VESOLE DH, CHANDRASEKAR P et al.: A multicenter trial of posaconazole vs. fluconazole for the prophylaxis of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation with GVHD. Mycoses (2005) 48(Suppl. 2):26-27.
167. CORNELY O, WINSTON D, PERFECT J et al.: Posaconazole vs standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. Blood (2005):106.
168. KRISHNA G WD, COURTNEY R et al.: Posaconazole plasma concnetrations in pediatric subjects with invasive fungal infections. The 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, DC (2004).
169. BLUMER J HR, KRISHNA G et al.: Efficacy of posaconazole salvage therapy in pediatric subjects with invasive fungal infections. The 15th European Congress for Clinical Microbiology and Infectious Diseases European Society for Clinical Microbiology and Infectious Diseases (2005).
170. GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10(8):1545-1558.
171. STONE JA, HOLLAND SD, WICKERSHAM PJ et al.: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. (2002) 46(3):739-745.
172. SABLE CA, NGUYEN BY, CHODAKEWITZ JA, DINUBILE MJ: Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. (2002) 4(1):25-30.
173. MARR KA, HACHEM R, PAPANICOLAOU G et al.: Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Tanspl. Infect. Dis. (2004) 6(3):110-116.
174. TRENSCHEL R, DITSCHKOWSKI M, ELMAAGACLI AH et al.: Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant. (2005) 35:583-586.